Zaltrap

Product manufactured by Sanofi-Aventis U.s. Llc

Application Nr Approved Date Route Status External Links
BLA125418 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Zaltrap, In Combination With Fluorouracil, Leucovorin, Irinotecan-(Folfiri), Is Indicated For The Treatment Of Patients With Metastatic Colorectal Cancer (Mcrc) That Is Resistant To Or Has Progressed Following An Oxaliplatin-Containing Regimen. Zaltrap, A Vascular Endothelial Growth Factor Inhibitor, In Combination With Fluorouracil, Leucovorin, Irinotecan (Folfiri), Is Indicated For The Treatment Of Patients With Metastatic Colorectal Cancer That Is Resistant To Or Has Progressed Following An Oxaliplatin-Containing Regimen. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Aflibercept

Comments